LEVODOPA-INDUCED LOCAL CEREBRAL BLOOD-FLOW CHANGES IN PARKINSONS-DISEASE AND RELATED DISORDERS

被引:33
作者
KOBARI, M
FUKUUCHI, Y
SHINOHARA, T
OBARA, K
NOGAWA, S
机构
[1] Department of Neurology, School of Medicine, Keio University, Shinjuku-ku, Tokyo, 160
关键词
ARTERIOSCLEROTIC PARKINSONISM; CEREBRAL BLOOD FLOW; LEVODOPA; OLIVOPONTOCEREBELLAR ATROPHY; PARKINSONS DISEASE; PROGRESSIVE SUPRANUCLEAR PALSY;
D O I
10.1016/0022-510X(94)00237-I
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Local cerebral blood flow (CBF) in the steady state and after intravenous administration of levodopa (1 mg/kg) was measured by xenon-enhanced computed tomography in patients with Parkinson's disease (PD, n = 16), progressive supranuclear palsy (PSP, n = 6), olivopontocerebellar atrophy (OPCA, n = 5), and arteriosclerotic parkinsonism (AP, n = 7). Three patterns of local CBF changes following levodopa were observed: (1) diffuse CBF increases, especially in striatum and thalamus, as found in patients with PD; (2) no significant changes in CBF, as in patients with OPCA and AP; and (3) CBF reductions in basal ganglia and thalamus, as seen in patients with PSP. The CBF increases after levodopa in PD may be secondary to metabolic activation of the nigrostriatal dopaminergic system. The poor CBF responses in patients with OPCA, AP, and PSP appeared to reflect degeneration of the dopaminergic neurons and dopamine receptors to various degrees. The CBF increases, especially in striatum and thalamus, tended to be greater (not significant) among responders to oral levodopa therapy. Levodopa-induced CBF measurements may be useful for the differential diagnosis of parkinsonian syndromes of various etiologies, but are not necessarily sufficient for predicting outcomes of long-term levodopa therapy.
引用
收藏
页码:212 / 218
页数:7
相关论文
共 33 条
[21]   IMAGING LOCAL CEREBRAL BLOOD-FLOW BY XENON-ENHANCED COMPUTED-TOMOGRAPHY - TECHNICAL OPTIMIZATION PROCEDURES [J].
MEYER, JS ;
SHINOHARA, T ;
IMAI, A ;
KOBARI, M ;
SAKAI, F ;
HATA, T ;
ORAVEZ, WT ;
TIMPE, GM ;
DEVILLE, T ;
SOLOMON, E .
NEURORADIOLOGY, 1988, 30 (04) :283-292
[22]  
NIIMI T, 1979, Acta Neurologica Scandinavica Supplementum, V60, P158
[23]   TEMPORAL RELATIONSHIPS BETWEEN PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF LEVODOPA AND CLINICAL EFFECT IN PARKINSONS-DISEASE [J].
OLANOW, CW ;
GAUGER, LL ;
CEDARBAUM, JM .
ANNALS OF NEUROLOGY, 1991, 29 (05) :556-559
[24]  
PARKES JD, 1974, Q J MED, V43, P49
[25]   PRESYNAPTIC PARKINSONISM IN OLIVOPONTOCEREBELLAR ATROPHY - CLINICAL, PATHOLOGICAL, AND NEUROCHEMICAL EVIDENCE [J].
PASCUAL, J ;
PAZOS, A ;
DELOLMO, E ;
FIGOLS, J ;
LENO, C ;
BERCIANO, J .
ANNALS OF NEUROLOGY, 1991, 30 (03) :425-428
[26]   LOCAL CEREBRAL METABOLIC EFFECTS OF L-DOPA THERAPY IN 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE-INDUCED PARKINSONISM IN MONKEYS [J].
PORRINO, LJ ;
BURNS, RS ;
CRANE, AM ;
PALOMBO, E ;
KOPIN, IJ ;
SOKOLOFF, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5995-5999
[27]   MEASUREMENT OF REGIONAL CEREBRAL BLOOD FLOW WITH ANTIPYRINE-14C IN AWAKE CATS [J].
REIVICH, M ;
JEHLE, J ;
SKOLOFF, L ;
KETY, SS .
JOURNAL OF APPLIED PHYSIOLOGY, 1969, 27 (02) :296-&
[28]   DOPAMINERGIC AND CHOLINERGIC LESIONS IN PROGRESSIVE SUPRANUCLEAR PALSY [J].
RUBERG, M ;
JAVOYAGID, F ;
HIRSCH, E ;
SCATTON, B ;
LHEUREUX, R ;
HAUW, JJ ;
DUYCKAERTS, C ;
GRAY, F ;
MORELMAROGER, A ;
RASCOL, A ;
SERDARU, M ;
AGID, Y .
ANNALS OF NEUROLOGY, 1985, 18 (05) :523-529
[29]   I-123 IODOBENZAMIDE-SPECT PREDICTS DOPAMINERGIC RESPONSIVENESS IN PATIENTS WITH DENOVO PARKINSONISM [J].
SCHWARZ, J ;
TATSCH, K ;
ARNOLD, G ;
GASSER, T ;
TRENKWALDER, C ;
KIRSCH, CM ;
OERTEL, WH .
NEUROLOGY, 1992, 42 (03) :556-561
[30]   STUDIES ON METABOLISM OF D-ISOMERS AND L-ISOMERS OF 3,4-DIHYDROXYPHENYLALANINE (DOPA) .3. ABSORPTION DISTRIBUTION AND EXCRETION OF D-DOPA-C-14 AND L-DOPA-C-14 IN RATS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION [J].
SHINDO, H ;
NAKAJIMA, E ;
KAWAI, K ;
MIYAKOSHI, N ;
TANAKA, K .
CHEMICAL & PHARMACEUTICAL BULLETIN, 1973, 21 (04) :817-825